Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia
John R. Guyton, MD*,*,
B. Greg Brown, MD, PhD ,
Sergio Fazio, MD, PhD ,
Adam Polis, MA ,
Joanne E. Tomassini, PhD and
Andrew M. Tershakovec, MD, MPH
* Department of Medicine, Duke University Medical Center, Durham, North Carolina
Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington
Vanderbilt Lipid Laboratory, Vanderbilt University Medical Center, Nashville, Tennessee
Clinical and Quantitative Sciences, Merck & Co., Inc., North Wales, Pennsylvania.
View larger version (57K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Patient Disposition
AE = adverse experience; ALT = alanine aminotransferase; AST = aspartate aminotransferase; LDL-C = low-density lipoprotein cholesterol; mITT = modified intent-to-treat population; TSH = thyroid stimulating hormone; wk = week.
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Time and Dose Effects
Percent change from baseline in (A) low-density lipoprotein cholesterol (LDL-C), (B) high-density lipoprotein cholesterol (HDL-C), and (C) triglycerides (TG) during 24 weeks. E/S = ezetimibe/simvastatin.
|
|
|
